Pulse-chase studies of [3S]cysteine-labeled fibrillin were performed on fibroblast strains from 55 patients with Marfan syndrome (MFS), including 13 with identified mutations in the fibrillin-1 gene and 10 controls. Quantitation of the soluble intracellular and insoluble extraceliular fibrillin allowed discrimination of five groups. Groups I (n = 8) and H (n = 19) synthesize reduced amounts of normal-sized fibrillin, while synthesis is normal in groups m (n = 6), IV (n = 18), and V (n = 4). When extracellular fibrillin deposition is measured, groups I and III deposit between 35 and 70% of control values, groups II and IV < 35%, and group V > 70%.
Introduction musculoskeletal, and cardiovascular systems ( 1) . Several years ago, Sakai et al. (2) isolated fibrillin from the culture medium of dermal fibroblasts and provided substantial evidence for this protein to be the major component of 10-nm microfibrils. Microfibrils are abundant in elastic and non-elastic tissues in organs that are significantly affected in patients with the Marfan syndrome. A dramatic decrease in the amount of such microfibrils has previously been demonstrated in the skin and in cultured fibroblasts from such patients (3) .
Genetic linkage studies with random probes mapped the MFS locus to chromosome 15 (4) . The fibrillin cDNA was cloned (5) and mapped to the same site on human chromosome 15 by in situ hybridization (6) . Subsequently, genetic linkage was established between the Marfan syndrome and the fibrillin gene (FBNI) on chromosome 15 by using intragenic markers (7) . Several unique and independent missense, nonsense, and deletion mutations in FBNJ have been reported, which make a strong argument for the primary involvement of this large gene in the causation of MFS (8) (9) (10) (11) (12) (13) (14) . The basis for considerable intra-and interfamilial phenotypic variability remains unknown. Unique beaded microfibrils (2, 3, 15) are the presumptive functional units that are affected. Even though the beaded microfibril presumably contains other proteins in addition to fibrillin ( 16) , all linkage studies and mutational analyses to date point to the FBN1 gene as the major locus responsible for the phenotype.
MFS is an autosomal dominant disorder in patients heterozygous for mutations at the FBNJ locus and, therefore, the normal allele is expected to produce fibrillin mRNA of normal size and amount. It is not known whether null mutations exist and cause MFS that do not produce mutant fibrillin and that allow unimpeded matrix deposition of wild-type fibrillin made from the normal allele. In contrast, a mutant allele that gives rise to defective fibrillin molecules could interfere with normal fibrillogenesis and affect the integrity of the microfibrils by a dominant negative mechanism (17) , similar to that postulated for certain types of osteogenesis imperfecta (18) . No direct evidence has been provided as yet, however, to prove that this mechanism plays a role in the pathogenesis of MFS. McGookey Milewicz et al. (19) have previously reported variable abnormalities in cultured fibroblasts from patients with MFS with respect to the rate of synthesis, secretion and the amount of fibrillin in the extracellular matrix. Implied pathogenetic mechanisms were not correlated with genotype. In a recent study we have determined that missense mutations involving cysteine residues in the FBNJ gene result in delayed fibrillin secretion, but this may not be the most important effect of such mutations (20) .
Here we report a comprehensive study of 55 (21) , and 10 normal controls were selected for study from the Marfan Syndrome Clinic of the Stanford University Hospital, the Northern California Chapter of the National Marfan Association and the Johns Hopkins Medical Center (Baltimore, MD). These include nine fibroblast strains with missense mutations (20) and four with various other mutations as described recently (11, 13, 14) .
Cell culture and pulse-chase labeling. Skin value±2 SD, Table I ; see data presented below in Figs. 2 and 3 A). Likewise, "decreased deposition" was defined as the amount of fibrillin incorporated into the extracellular matrix being < 70% of controls (control value±2 SD, Table I ; compare also Figs. 2 and 3 B) . In control fibroblasts, the amount of intracellular fibrillin after a 4-h chase was 18±4.8% compared with that at time 0. When > 30% of fibrillin was retained inside the cells at the 4-h time point, we defined this as "delayed secretion" (20). Cells displaying this altered secretion pattern were found in groups Ill and IV (see data below in Fig. 2 , C'
and D').
Fibrillin metabolism in MFS fibroblasts
Based on the amounts of fibrillin synthesized and incorporated into the extracellular matrix, the 55 patients could be divided into five groups ( (Fig. 3 B) . Fibroblasts from two of the six patients in this group showed a delay in secretion as defined above (Fig. 2 C' ). The amount of fibrillin in the ECM is 35-70% in groups I and III, and < 35% in groups II and IV. Group V is indistinguishable from controls.
Group IV: Normal synthesis and severely impaired deposition offibrillin. Similar to group III, fibroblasts of group IV (n = 18) generate normal amounts of the 350-kD fibrillin polypeptide (Table I, Figs. 2 D and 3 A) . In six of the 18 cell strains, however, fibrillin secretion was found to be delayed (Fig. 2  D' ). In contrast to group III and regardless of the secretion phenotype, the amount of fibrillin in the matrix is drastically reduced to < 35% of normal in all of the group IV fibroblasts (Fig. 3 B) . fibrillin allowed us to investigate the effects of cell density and of intra-and extracellular fibrillin concentration on the synthesis and deposition of fibrillin. We plated different numbers of fibroblasts from a group I patient and from a control individual. The cells were labeled as described, and after a 20-h chase period, the NP-40-insoluble extracellular components were harvested. In control fibroblasts, the incorporation of fibrillin into the extracellular matrix increases with increasing cell numbers and reaches a plateau (Fig. 4) . In the group I fibroblasts, fibrillin deposition also increases with cell number, but the amount of newly deposited fibrillin in the extracellular matrix is only approximately half the amount of that of normal fibroblasts at all the cell numbers tested. This suggests that, at least under the conditions of hyperconfluent cell culture, fibrillin expression and deposition are both constitutive, strictly gene-dosage dependent and are not subject to feedback by either concentrations of soluble fibrillin or amount of microfibrillar material. To indicate that in group I fibroblasts the lower amount of insoluble fibrillin is due to lower fibrillin production, we have called this "product effect." Fibrillin appears to be deposited in the extracellular matrix with similar efficiency even in cells that make fewer normal fibrillin molecules. The observed reduced deposition in group I cells could thus simply be due to fewer available fibrillin molecules.
Groups 11 and IV: Interference by abnormal fibrillin molecules with normal microfibrillar assembly ("Medium exchange"). In groups II and IV, < 35% of de novo synthesized fibrillin is deposited in the extracellular matrix compared to 100+10% in controls (Table I and Figs. 2 and 3 ). This result could be explained if the mutant allele gives rise to abnormal protein molecules that interfere with fibrillogenesis. Under this hypothesis, group II fibroblasts are expected to make normal fibrillin (the product of the normal allele) in addition to a truncated abnormal fibrillin polypeptide, which we would not have detected in the pulse-chase experiments. Group IV fibroblasts, on the other hand, would make both normal and full-size, but altered, fibrillin molecules. In both instances, the abnormal protein product might affect microfibrillar assembly. Fig.  5 , the incorporation of labeled normal fibrillin molecules into the extracellular matrix of unlabeled MFS fibroblasts, which continue to make fibrillin products during the 20-h incubation, was considerably reduced for groups II and IV in contrast to cells from groups I, III, or V. These results resemble the data presented above on the direct analysis of fibrillin deposition in MFS from the various groups (Fig. 2) . It suggests either interference with matrix deposition by an abnormal fibrillin product, as discussed above, or less efficient "binding" of normal fibrillin molecules under medium exchange conditions to a MFS matrix of group II and IV cells that, by definition, contains less insoluble fibrillin.
Purification of a truncated form offibrillin from group II fibroblasts. To determine, whether the media of group I and II MFS fibroblasts contain truncated fibrillin molecules, we labeled group II (n = 15), group I (n = 3), and control fibroblasts (n = 2) continuously for 16 h with 50 uCi/700 il of [35S]_ cysteine. The culture medium of each cell strain was then passed over a fibrillin antibody immunoaffinity column and the eluates were analyzed by both 4.5 and 10% SDS-PAGE. While we were able to isolate a single 350-kD fibrillin polypeptide species from all of the cells, the eluate from the mab69 antibody column of one of the group II fibroblasts contained two labeled bands, one at 350 kD and the other at -60 kD (Fig. 6) . The 60 kD polypeptide was not seen in eluates from control cells or any of the other MFS fibroblasts and, thus, does not seem to be an intra-or extracellularly processed form or degradation product of fibrillin. The 60-kD band most likely represents a truncated fibrillin molecule due to an as yet unidentified FBNI mutation. From the intensity of the radioactive band we estimate that the amount of the "short" fibrillin product could correspond to 
Discussion
The discovery of different types of mutations in the FBN1 gene have proven the causal relationship between fibrillin abnormalities and the autosomal dominant Marfan syndrome (8) (9) (10) (11) (12) (13) (14) . Previously, cells from several MFS patients were shown to either produce shortened fibrillin molecules (10) , to produce less, to deposit less, or to secrete fibrillin more slowly (19) . In addition to these latter three alterations in biosynthesis, the existence of a fibrillin precursor was postulated based on a difference in molecular weight between the intra-and extracellular form (19) . The latter observation has not been confirmed in other studies ( 15, 20) , nor did we find evidence for profibrillin here. In our preliminary studies we experienced difficulties in making assignments to the three basic groups described by McGookey Milewicz et al. ( 19) . By applying quantitative pulse-chase labeling of fibroblasts we have found now that patidnts diagnosed with MFS can be subdivided into five groups. Since four of these five groups contain samples with known FBN1 mutations, correlations between protein phenotype and pathogenetic mechanisms could also be made. Fibroblasts in groups I and H account for 50% of the MFS samples studied here. These cells make half the amount of fibrillin as compared with controls. The two groups are distinguished by the amount of fibrillin that becomes insoluble during the 20-h chase period. While the group I phenotype shows one half of normal deposition, this value is even lower in group II. The major difference between these two groups appears to be related to the amount of mutant transcript and protein derived from the mutant allele. Evidence for this comes from four patients with known FBNI mutations (13 ; Table II ). As has been observed also for other disease genes (23, 24) , certain mutations affect transcript levels. In one group I patient, an insertion of four nucleotides leads to a frameshift and premature termination codon, which results in transcript levels of only 6% of normal (13) . The amount of abnormal protein made by this mutant transcript has not been determined, but it is likely to be also very low. Three mutations have been identified in group II patients. Two of them, -2448 (247)G + 1 to A and 770(3464)dell7, create frameshifts and premature signals for termination of translation of mRNA and both result in transcript levels of -15% of normal (13, 14) . The third, 3645(6339)T to G, a nonsense mutation that leads to in-frame skipping of exon 51 (11) , generates 25% of mutant mRNA. The amount of transcript in the three mutations of group II are higher as compared with group I, suggesting that a corresponding larger amount of altered protein in group II may be responsible for the significantly lower deposition of fibrillin in this group (13 ;  Table II) .
Our experiments on the "product effect" show that a decrease in synthesis and/or deposition of fibrillin does not seem to lead to compensatory changes in fibrillin metabolism. Thus, a low amount or total lack of mutant product would result in a group I and possibly mild disease phenotype due to a 50% decrease of extracellular fibrillin and an overall reduction in microfibrils (Fig. 7) . This would be analogous to cases of osteogenesis imperfecta with a nonfunctional allele for pro-a 1 (I) chains of type I collagen (25) .
Altered fibrillin products in group II fibroblasts, however, seem to act as competitive inhibitors of microfibrillar assembly and result in < 35% deposition. A plausible explanation for the pathogenetic effect of the documented mutations that lead to truncated proteins is based on a "dominant negative" mechanism. As shown for a number of other disorders (17, 18, 26, 27) , the abnormal product of the mutant allele interferes with 'dominant negative, IV x mS Figure 7 . Schematic representation of postulated pathogenetic mechanisms in MFS. In control cells, the products of both alleles are normal fibrillin molecules that are assembled into microfibrils extracellularly. Group I cells make fibrillin from the normal allele and either fail to synthesize any product from the mutant allele or make a (truncated) product that is not secreted or that is present in only low amounts (due to decreased transcript stability, inefficient secretion or intracellular degradation of the protein product). The normal fibrillin molecules are deposited in the extracellular matrix with normal efficiency, but fewer fibrils are formed ("product effect"). In group II, truncated fibrillin molecules are secreted and interfere with microfibril formation by a "dominant negative" mechanism. Abnormal fibrils of lower stability or very few normal fibrils are made. In group III, two possible mechanisms could be operating. One, mutations causing minimal effects on fibrillin structure could lead to microfibrils formed from both normal and mutant fibrillin molecules, or two, similar to group I, mutant fibrillin molecules are degraded and reduced amounts of normal microfibrils are deposited. In group IV, mutant fibrillin molecules of normal size are secreted and interfere with fibrillogenesis by a "dominant negative"
mechanism.
the function of the normal protein, the product of the normal allele. To obtain experimental evidence, we have attempted to interfere with fibrillin deposition by "medium exchange" experiments and to isolate abnormal fibrillin products with antibodies. The former experiment yielded satisfying results by demonstrating that low levels of fibrillin deposition are only seen in group II and IV fibroblasts and not in the other three groups. This low fibrillin deposition could be due to a true dominant negative effect, namely inhibition by abnormal fibrillin products. It could also be related to a large reduction in (Fig. 7) .
In four of the 55 fibroblast strains no defect in fibrillin metabolism could be identified with the pulse-chase method. All four were sporadic cases and, therefore, linkage studies with polymorphic markers from the FBN1 locus were not possible.
We are considering two possibilities to explain this finding. Firstly, some proteins, such as elastin (28) , thrombospondin (29) (33) . Although linkage evidence for genetic heterogeneity in the Marfan syndrome has not been reported to date, alteration of the structure or expression of these proteins or other, as yet unknown proteins associated with microfibrils, could affect the microfibril functionally and could cause clinical features similar to those seen in MFS. Secondly, in these four patients we have only examined the amount of insoluble fibrillin. It is possible that in group V, the defect is not seen as an abnormality in amount, but rather in quality or function of the microfibrils.
We have found defects in fibrillin metabolism of cultured fibroblasts in 93% of the patients with MFS by this quantitative pulse-chase method. This success rate contrasts with the relatively small fraction of patients for whom mutations have been defined at the mRNA level using denaturing gradient gel electrophoresis or single strand conformation analysis of RT-PCR products and direct sequencing of such products (14) . With one exception (8) 
